CALIXAR and VirPath develop an innovative manufacturing process for high performance influenza vaccines

September 23, 2014

A new antigens formulation against pandemic flu (A H1N1 virus) proved six times more effective than other vaccines.

Share this post

Secure and boost
your discovery programs

Starting from native material or recombinant systems, we succeed with all types of proteins: Kinases, Phosphatases, Ubiquitins, Epigenetic Proteins, GPCRs, Ion Channels, Transporters, Receptors and Viral Proteins.